20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

In estrogen-receptor (ER)–positive early-stage breast cancer, 5 years of adjuvant endocrine therapy substantially reduces the risks of locoregional and distant recurrence, contralateral breast cancer, death from breast cancer, and hence death from any cause. In trials of 5 years of tamoxifen…

http://ift.tt/2zqRnIq